ARQT Q3 2025 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$99M+121.7% YoY

Gross Profit

$91M91.2% margin

Operating Income

$9M8.6% margin

Net Income

$7M7.5% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+21.7%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$371M

Total Liabilities

$213M

Stockholders' Equity

$158M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$99M	$45M	+121.7%
Gross Profit	$91M	$39M	+130.6%
Operating Income	$9M	-$39M	+121.8%
Net Income	$7M	-$42M	+117.8%